Zydus Lifesciences gets USFDA approval for Azilsartan Medoxomil and Chlorthalidone tablets

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil and Chlorthalidone tablets, 40 mg/12.5 mg and 40 mg/25 mg.

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil and Chlorthalidone tablets, 40 mg/12.5 mg and 40 mg/25 mg.

The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ – II, India.

Zydus Lifesciences stock rose 1.02 per cent on the NSE to trade at ₹1,101.65 as of 12.19 pm.

Like (0)
Previous June 18, 2024 9:43 am
Next June 18, 2024 9:43 am

Related posts